MBC BioLabs is Excited to Welcome Codex DNA as its Newest Partner.
ANNOUNCEMENT
New Company at 953 Indiana
Events
Future Founders in Life Sciences Presents Trevor Martin of Mammoth Biosciences
Continuing our new lecture series in partnership with Y Combinator, we're excited to bring you Dr. Trevor Martin, CEO and Co-founder of Mammoth Biosciences. His team is doing fascinating work on new CRISPR applications.
Asher Bio Launches with $55 Million Series A Financing
Asher Biotherapeutics, a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases, today announced its launch following a $55 million Series A financing led by Third Rock Ventures with participation from Boxer Capital of Tavistock Group, Invus, Y Combinator and MBC Biolabs.
The Servier Golden Ticket Award is a competitive process aiming to foster, support and accelerate promising entrepreneurial innovation in Servier's therapeutic areas of focus. The Golden Ticket winner will gain priority admission or renewal and a voucher for one year of incubator space. Winners also have access to Servier's Research and Development mentorship.
Ono Pharmaceutical Co., Ltd. (ONO) and Ono Venture Investment, Inc. (OVI), its corporate venture capital arm to learn about innovation at the company, including ONO's R&D, therapeutic and platform technology focus areas, science-led investment strategy and collaborative partnering approach – launching the call for Golden Ticket Competition entries to help accelerate innovative life science start-ups into real business that can bring value to patients.
MBC BioLabs is Excited to Welcome Codex DNA as its Newest Partner.
MBC BioLabs is excited to welcome Codex DNA as its newest partner. Codex DNA's BioXp™ 3250 System will be available at the MBC BioLabs San Carlos. The BioXp™ 3250 system provides hands-free, end-to-end automation of DNA assembly, cloning, and amplification in a single overnight run. The award-winning BioXp™ 3250 system accelerates the design-build-test phases of the product development cycle by enabling automated, rapid, high-throughput synthesis of genes, clones, and variant libraries. The BioXp™ system is designed to improve productivity, reduce turnaround time, increase throughput and scale, enhance quality, and enable complete workflow control for both synthetic DNA and mRNA formats.
New Company at 953 Indiana
Foundery Innovations is an emerging company focused on knowledge-based prioritization and prosecution of target opportunities in the growing immunotherapy space. Integrating the immunology expertise and decades of therapeutic development background of the founders, we are expediting the timelines required for an academic concept to become a drug candidate. Foundery develops biologics with the potential to cure high unmet need diseases caused by an imbalance in immunity.
